Allergan Inc. (AGN) March 28, 2012 1:00 pm ET Executives Unknown Executive - Scott M. Whitcup - Chief Scientific Officer and Executive Vice President of Research & Development David E.I. Pyott - Chairman, Chief Executive officer and President Cornelia Haag-Molkenteller - Mitchell Brin - Frederick Beddingfield - Gregory H. Altman - Founder, Chief Executive Officer, President and Director Analysts David Risinger - Morgan Stanley, Research Division David Amsellem - Piper Jaffray Companies, Research Division Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division Shibani Malhotra - RBC Capital Markets, LLC, Research Division Douglas D. Tsao - Barclays Capital, Research Division John T. Boris - Citigroup Inc, Research Division Gary Nachman - Susquehanna Financial Group, LLLP, Research Division Catherine J. Arnold - Crédit Suisse AG, Research Division Unknown Analyst Seamus Fernandez - Leerink Swann LLC, Research Division David G. Buck - The Buckingham Research Group Incorporated Christopher Schott - JP Morgan Chase & Co, Research Division Gregory B. Gilbert - BofA Merrill Lynch, Research Division Annabel Samimy - Stifel, Nicolaus & Co., Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Gregory Waterman - Goldman Sachs Group Inc., Research Division PresentationUnknown Executive So I wanted to welcome everyone to the 2012 R&D Technology Review. Just find your seats. And with that, I'd like to introduce Dr. Scott Whitcup. Scott M. Whitcup
Well, thank you, Jim, and I want to thank everyone for coming out to our R&D Technology Review. As you know, what we try to do in these is give you insight into some of the pipeline that some of you haven't seen before and some balance. We'll have some updates on late-stage programs, but importantly give you some look at early-stage science as well. I want to start by introducing myself. I'm Scott Whitcup, I'm the Executive Vice President of R&D and Chief Scientific Officer and lead the group on Pharma and Medical Device side and want to start off by thanking the vast number of scientists and clinical developers who really did all the work on the science and clinical trials that we present today, and also a thanks to the IR staff, especially Joann Bradley and David Nakasone who really helped organize this.